Nanoplasmonics for Enhanced Fluorescence Detection of Nucleic Acids: From Fundamentals to Boosting Cancer Management

IF 4 Q2 ENGINEERING, BIOMEDICAL

Advanced Nanobiomed Research Pub Date : 2025-01-23 DOI:10.1002/anbr.202400088

David Botequim, Rui Oliveira-Silva, Vanda Vaz Serra, Peter Zijlstra, Duarte Miguel de França Prazeres, Pedro Miguel Ribeiro Paulo

{"title":"Nanoplasmonics for Enhanced Fluorescence Detection of Nucleic Acids: From Fundamentals to Boosting Cancer Management","authors":"David Botequim, Rui Oliveira-Silva, Vanda Vaz Serra, Peter Zijlstra, Duarte Miguel de França Prazeres, Pedro Miguel Ribeiro Paulo","doi":"10.1002/anbr.202400088","DOIUrl":null,"url":null,"abstract":"<p>Cancer remains a leading cause of mortality and morbidity worldwide. Consequently, the scientific community continues to pursue improvements in diagnostic methods and subsequent treatments. To enhance treatment efficacy and reduce the probability of adverse outcomes, reliable and sensitive diagnostic methods are essential. A potential solution may lie in the synergy between nanotechnology and optical biosensors, as they can provide exceptional sensitivity in the detection of disease biomarkers. This review focuses on fluorescent DNA probes assembled onto metal nanoparticles for cancer-related applications. These hybrid biosensors exhibit remarkable and versatile optical properties enabling to enhance signal emission by orders of magnitude. In these configurations, metallic particles function as optical antennas for fluorescent dyes, significantly increasing their photon emission rates. This review presents a novel perspective on recent advancements in cancer diagnostics and treatment utilizing hybrid biosensors. Current methodologies for cancer diagnostics are examined, toward elucidating their advantages and limitations. The subject matter is critically evaluated, and fundamental concepts are explored to assess the most promising avenues for clinical applications. These biosensors may potentially integrate into medical practice and healthcare in the near future, both for the diagnosis and prognosis of cancer, as well as for precision (P4) medicine.</p>","PeriodicalId":29975,"journal":{"name":"Advanced Nanobiomed Research","volume":"5 2","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202400088","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Nanobiomed Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/anbr.202400088","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Cancer remains a leading cause of mortality and morbidity worldwide. Consequently, the scientific community continues to pursue improvements in diagnostic methods and subsequent treatments. To enhance treatment efficacy and reduce the probability of adverse outcomes, reliable and sensitive diagnostic methods are essential. A potential solution may lie in the synergy between nanotechnology and optical biosensors, as they can provide exceptional sensitivity in the detection of disease biomarkers. This review focuses on fluorescent DNA probes assembled onto metal nanoparticles for cancer-related applications. These hybrid biosensors exhibit remarkable and versatile optical properties enabling to enhance signal emission by orders of magnitude. In these configurations, metallic particles function as optical antennas for fluorescent dyes, significantly increasing their photon emission rates. This review presents a novel perspective on recent advancements in cancer diagnostics and treatment utilizing hybrid biosensors. Current methodologies for cancer diagnostics are examined, toward elucidating their advantages and limitations. The subject matter is critically evaluated, and fundamental concepts are explored to assess the most promising avenues for clinical applications. These biosensors may potentially integrate into medical practice and healthcare in the near future, both for the diagnosis and prognosis of cancer, as well as for precision (P4) medicine.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Advanced Nanobiomed Research nanomedicine, bioengineering and biomaterials-

CiteScore

5.00

自引率

5.90%

发文量

审稿时长

21 weeks

期刊介绍： Advanced NanoBiomed Research will provide an Open Access home for cutting-edge nanomedicine, bioengineering and biomaterials research aimed at improving human health. The journal will capture a broad spectrum of research from increasingly multi- and interdisciplinary fields of the traditional areas of biomedicine, bioengineering and health-related materials science as well as precision and personalized medicine, drug delivery, and artificial intelligence-driven health science. The scope of Advanced NanoBiomed Research will cover the following key subject areas: ▪ Nanomedicine and nanotechnology, with applications in drug and gene delivery, diagnostics, theranostics, photothermal and photodynamic therapy and multimodal imaging. ▪ Biomaterials, including hydrogels, 2D materials, biopolymers, composites, biodegradable materials, biohybrids and biomimetics (such as artificial cells, exosomes and extracellular vesicles), as well as all organic and inorganic materials for biomedical applications. ▪ Biointerfaces, such as anti-microbial surfaces and coatings, as well as interfaces for cellular engineering, immunoengineering and 3D cell culture. ▪ Biofabrication including (bio)inks and technologies, towards generation of functional tissues and organs. ▪ Tissue engineering and regenerative medicine, including scaffolds and scaffold-free approaches, for bone, ligament, muscle, skin, neural, cardiac tissue engineering and tissue vascularization. ▪ Devices for healthcare applications, disease modelling and treatment, such as diagnostics, lab-on-a-chip, organs-on-a-chip, bioMEMS, bioelectronics, wearables, actuators, soft robotics, and intelligent drug delivery systems. with a strong focus on applications of these fields, from bench-to-bedside, for treatment of all diseases and disorders, such as infectious, autoimmune, cardiovascular and metabolic diseases, neurological disorders and cancer; including pharmacology and toxicology studies.